Skin Cancer options… from the egg plant!

Skin Cancer options…  from the egg plant!

 

 

 

Curaderm-BEC5 is a topical cream that can successfully eliminate many non Melanoma basal cell carcinomas, SCC’s (squamous cell carcinomas) and keratosis in humans.

Curaderm-BEC5 is a less painful, non disfiguring and significantly less expensive alternative to conventional surgery, chemotherapy and laser treatments.

By using Curaderm-BEC5 you may not need Surgery, Radiotherapy or other conventional treatment methods. To hear what our customers say about Curaderm-BEC5, click here to read their testimonials.

In the past 30 years Skin Cancer Rates in Causasians living around the world have more than doubled. The issue of looking after your skin is important to your health. Curaderm-BEC5 seems to destroy skin cancer cells with no dangerous side effects and little to no scarring. Leaving skin cancer untreated could lead to painful surgery and amputations.

Curaderm-BEC5 is 99.8% Natural, with only a small amount of preservative to ensure stability and extend it’s shelf life.

Curaderm-BEC5 is one of the few natural products that have undergone pharmaceutical grade research and development.

Example of Curaderm-BEC5 Effectiveness

The patient has been suffering from several BCC (basal cell carcinomas) lesions for at least 12 months before treatment started

Independent medical experts advised that the cancer could be surgically removed and that the patient would either completely loose her nose (replaced with a fake nose) or undergo major plastic surgery.
Curaderm-BEC5 cream was applied twice daily on the surface of the lesion.

After Curaderm treatment for 13 weeks the BCC (basal cell carcinomas) lesions were no longer existent. The Curaderm had killed all the cancer cells.

This patient’s progress has now been monitored for a further 10 years and there was no recurrence of the non melanoma skin cancer.

The Skin Cancer Treatment Resources

Useful Resources
More about Curaderm-BEC5

Compare Curaderm-BEC5 with Conventional Skin Cancer Treatments
Features and Benefits of using Curaderm-BEC5
Safety of Curaderm-BEC5
Professional Testimonials
Customer Testimonials
Curaderm-BEC5 Forum Discussion

 

REFERENCES
Bill E. Cham
Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and Necrosis. Treatment for Skin Cancer and Hope for Internal Cancers Research Journal of Biological Sciences 2 (4): 503-514, 2007

 

Cham, B. E. and Wilson, L. (1987) HPLC of glycoalkaloids from Solanum sodomaeum L. Planta Med. 53, 59-61

 

Bajaj, K. L., Kaur, G. and Chada, M. L. (1979). Glycoalkaloid content and other chemical constituents of the fruits of some egg plant (Solanum melongena, L.) varieties. J. Plant Foods, 3, 163-168

 

Chen, Z. and Miller, A. (2001) Steroidal Alkaloids in solanaceous vegetable crops. (2001). Horticul. Rev. 25. 171-186

 

Cipollini, M. L. (2000) Secondary metabolites of vertebrate – dispersed fruits; evidence for adaptive functions. Rev. Chil. Hist. Nat. 73. 421-440

 

Ghazi, M. and Matthees, D. P. (1989) Use of ion-pairing reversed-phase liquid chromathography in separation of solanidine and solasodine. J. Chem. Exol. 15. 2661-2666

 

Jones, P.G. and Fenwick, G.R. (1981) The glycoalkaloid content of some edible Solanaceous fruits and potato products. J. Sci, Food Agric. 32. 419-421

 

Lequart, V., Goethals, G., Banoub, J., Villa, P. and Martin, P. (2004) An Improved Synthesis of Chacotriose. Chem. Let. 33. 444

 

Morillo, M., Lequart, V., Grand, E., Goethals, G., Usubillaga, A., Villa, P. and Martin, P. (2001) Synthesis of peracetylated chaco-triose. Carbohyd. Res. 334, 281-287

 

Nada, C., Nikolic, A., Mihajlo, Z., Stankovic, A. G., Dejan, Z. and Markovic, C. D. (2005) Liquid-liquid systems for acid hydrolysis of glycoalkaloids from Solanum tuberosum L. tuber sprouts and solanidine extraction. Med. Sci. Monit. 11(7). BR200-205

 

Schreiber, K. (1968) Steroidal alkaloids: The Solanum group. In the alkaloids Vol 10, (Mansk, K., Ed.). Academic Press.

 

Cham, B. E. (1988) Monograph on the compound BEC. Drugs of the Future. 13, 714-716

 

Daunter, B. and Cham, B. E. (1990) Solasodine glycosides. In vitro preferential cytotoxicity for human cancer cells. Cancer Letters 55, 209-220

 

Cham, B. E. (1989) Curaderm (antineoplastic). Launched in Australia. Drug News and Perspectives 2, 112

 

Cham, B. E. (1991) Solasodine glycosides: A new modality for cancer. In Proc. 2nd Oceania Symposium. p.30-36. Editor Mark S. Walker. Bioconcepts Publishing.

 

Cham, B. E. (1994) Solasodine glycosides as anti-cancer agents: Pre-clinical and clinical studies. Asia Pacif. J. Pharmacol. 9, 113-118

 

Cham, B. E. (1993) Efficacy and mode of action of solasodine glycosides (BEC) on cancer cells. In Proc. 4th Oceania Symposium 0041-51. Editor Mark S. Walker. Bioconcepts Publishing.

 

Chataing, B., Christancho, N. B. and Usubillaga, A. (1998) Topical treatment of herpes simplex, herpes zoster and genital herpes with a mixture of Solanaceous glycoalkaloids. MedULA. Universidad de Los Andes. 7. 30-34

 

Choi, E. and Koo, S. (2005) Anti-nociceptive and anti-inflammatory effects of the ethanolic extract of potato (Solanum tuberosum). Food Agri. Immun. 16. 29-39

 

Hall, C. A., Hobby, T. and Cipollini, M. (2006) Efficacy and Mechanisms of a- Solasonine-and a-Solamargine-Induced Cytolysis on Two Strains of Trypanosoma cruzi. J.Chem. Ecol. 32. 2405-2416

 

Kuo, K. W., Hsu, S. H., Li, Y. P., Lin, W. L., Liu, L. F., Chang, L. C., Lin, C. C., Lin, C. N. and Sheu, H. M. (2000). Anticancer activity evaluation of the Solanum glycoalkaloid solamargine. Triggering apoptosis in human hepatoma cells. Biochem. Pharmacol. 60, 1865-1873

 

Putalun, W., Taura, F., Qing, W., Matsushita, H., Tanaka, H and Shoyama, Y. (2003) Anti-solasodine glycoside single-chain Fv antibody stimulates biosynthesis of solasodine glycoside in plants. Plant Cell Rep. 22. 344-349

 

Verpoorte, R. (1998). Exploration of nature’s chemodiversity: the role of secondary metabolites as leads in drug development. Drug Discov. Today 3, 232-238

 

Vijayan, P., Vinod Kumar, S., Dhanaraj, S. A., Badami, S. and Suresh, B. In Vitro Cytotoxicity and Anti-tumour Properties of the Total Alkaloid Fraction of Unripe Fruits of Solanum pseudocapsicum. Pharmaceut. Biol. 40. 456-460

 

Cham, B. E., Gilliver, M. and Wilson, L. (1987) Antitumour effects of glycoalkaloids isolated from Solanum sodomaeum L. Planta Med. 53, 34-36

 

Cham, B. E., Daunter, B. (1990) Solasodine glycosides. Selective cytoxicity for cancer cells and inhibition of cytotoxicity by rhamnose in mice with sarcoma 180. Cancer Letters, 55, 221-225

 

Amalfi, C. (2006) The little mouse who wouldn’t say die. Cosmos Mag. 471.

 

Badami, S., Manohara Reddy, S.A., Kumar, E.P., Vijayan, P. and Suresh, B. (2003) Antitumour activity of total alkaloid fraction of Solanum pseudocapsicum leaves. Phytother. Res. 17. 1001-1004

 

Chataing, B., Concepcion, J. L., Lobaton, R. and Usubillaga, A. (1998) Inhibition of Trypanosomer cruzi growth in vitro by Solanum alkaloids; a comparison with ketoconazole. Planta Med. 64, 31-36

 

Chami, L.A., Méndez, R., Chataing, B., O’Callaghan, J., Usubillaga, A. and LaCruz, L. (2003) Toxicological effects of a-solamargine in experimental animals. Phyto Res. 17, 254-258

 

Chang, L. C., Tsai, T. R., Wang, J. J., Lin, C. N. and Kuo, K. W. (1998) The rhamnose moity of solamargine plays a crucial role in triggering cell death by apotosis. . Biochem. Biophys. Res. Commun. 242, 21-25

 

Esteves-Souza, A., Silva, T. M. and Alves, C. C. F. et al. (2002) Cytotoxic activities against Ehrlich carcinoma and human K562 leukaemia of alkaloids and flavonoids from two Solanum Species. J. Braz. Chem. Soc. 13. 838-842

 

Hsu, S. H., Tsai, T. R., Lin, C. N., Yen, M. H. and Kuo, K. W. (1996) Solamargine purified from Solanum incanum Chinese herb triggers gene expression of human TNFR1 which may lead to cell apoptosis. Biochem. Biophys. Res. Commun. 229, 1-5

 

Evans, R., Cham, B. E. and Daunter, B. (1989) Letter to the Editor. Your Pharmacy, January

 

Cham, B. E. and Meares, M. M. (1987) Glycoalkaloids from Solanum sodomaeum L. are effective in the treatment of skin cancers in man. Cancer Letters 36, 111-118

 

Cham, B. E., Daunter, B and Evans, R. (1992) Topical treatment of malignant and premalignant skin cancers by very low concentration of a standard mixture of solasodine glycosides. Clinical Digest Series. Dermatology. 1992

 

Cham, B. E., Daunter, B and Evans, R. (1991) Topical treatment of malignant and premalignant skin cancers by very low concentrations of a standard mixture of solasodine glycosides. Cancer Letters 59, 183-192

 

Cham, B. E., Daunter, B and Evans, R. (1990) Curaderm. Med. J. Australia. 152, 329-330

Cham, B. E., Daunter, B. (1990) Topical treatment of pre-malignant and malignant skin cancers with Curaderm. Drugs of Today 26, 55-58

 

Cham, B. E. (1989) Plants yield skin cancer cure. Austral. Technol. Rev. 2, 53

Millward, M., Powell, A., Daly, P., Tyson, S., Ferguson, R. and Carter, S. (2006) Results of phase I clinical trials of Coramsine in patients with advanced solid tumours. J. Clin. Oncol. 24, 2070

 

Nakamura, T., Komori, C., Lee, Y., Hashinoto, F., Yahara, S., Nohara, T., and Ejina, A. (1996) Cytotoxic activities of Solanum steroidal glycosides. Biol. Biopharm. Bull. 19, 564-566

 

Roddick, J. G., Rÿrenber, A. L. and Weissenberg, M. (1990) Membrane-disrupting properties of the steroidal glycoalkaloids Solasonine and Solamargine. Phyto. Chem. 29. 1513-1518

 

Roddick, J. G., Weissenberg, M. and Leonard, A. L. (2001) Membrane disruption and enzyme inhibition by naturally – occurring and modified chaco-triose – containing Solanum steroidal glycoalkaloids. Phyto Chem. 56, 603-610

 

Jellinek, N. and Maloney, M. (2005) Escharotic and other botanical agents for the treatment of skin cancer: A review J. Amer. Aca. Dermatol. 53. 486-495

 

Moss, R. W. (1998) Herbs against cancer History and controversy. Equinax press, Inc. Brooklyn, N.Y.

 

Punjabi, S., Cook, I., Kersey, P., Marks, R., Finlay, A., Sharpe, G. et al. (2000) A double blind, multi-centre parallel group study of BEC-5 cream in basal cell carcinoma. Eur. Acad. Dermatol. Venereol. 14 (Suppl), 47-60

 

Walsh, N. (2000) Promising Topical Therapy for Actinic Keratoses Brief Article Dr S Punjabi. Uni. Liverpool. Family Pratice News. December 1 article.

 

Williams, D. G. (1995) The skin cancer cure nobody wants you to know about. Alternatives, 6, 17-22. Mountain Home Publishing.

 

Williams, D. G. (1995). The skin cancer cure so effective, it’s being kept secret. Ingram, TX: Mountain Home Publishing.

 

Dr Calméz Ltd. Curaderm Website

Sussman, L.A.E. and Liggins, D.F. (1996) Incompletely excised basal cell carcinoma: a management dilemma? Aust. NZ. J. Surg. 66, 276-278

 

Cerio, R. and Punjabi, S. (2002) Clinical Appraisal of BEC5. Barts and The London NHS.

 

Ono, M., Nishimura, K., Suzuki, K., Fukushima, T., Igoshi, K., Yoshimitsu, H., Ikeda, T and Nohara, T. (2006) Steroidal Glycosides from the Underground Parts of Solanum Sodomaeum. Chem. Pharm. Bull. 54(2)230-233

Share This Post

      Curaderm-BEC5 is a topical cream that can successfully eliminate many non Melanoma basal cell carcinomas, SCC’s (squamous cell carcinomas) and keratosis in humans. Curaderm-BEC5 is a less painful, non disfiguring and significantly less expensive alternative to conventional surgery, chemotherapy and laser treatments. By using Curaderm-BEC5 you may not need Surgery, Radiotherapy or…
&source=WeeksMD">